| Quarter (USD) | Sep 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 127.39 mm | 127.39 mm | 127.39 mm | 127.39 mm | 127.39 mm | |
| Cash burn (monthly) | (no burn) | (no burn) | 5.80 mm | 3.51 mm | 961.17 k | |
| Cash used (since last report) | n/a | n/a | 16.33 mm | 9.88 mm | 2.71 mm | |
| Cash remaining | n/a | n/a | 111.05 mm | 117.51 mm | 124.68 mm | |
| Runway (months of cash) | n/a | n/a | 19.2 | 33.5 | 129.7 | |
| 13F holders | Current |
|---|---|
| Total holders | 11 |
| Opened positions | 4 |
| Closed positions | 23 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 60.50 mm |
| Total shares | 13.83 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 6.86 mm | $8.10 mm |
| 5am Ventures Iii | 2.01 mm | $4.01 mm |
| Canaan XII | 1.40 mm | $17.70 mm |
| Omega Fund V | 1.25 mm | $1.59 mm |
| Interwest Partners X | 903.74 k | $1.55 mm |
| Ra Capital Management | 703.08 k | $8.89 mm |
| BCLS Fund III Investments | 703.08 k | $8.89 mm |
| Manchester Capital Management | 470.00 | $5.05 mm |
| Pacifica Partners | 400.00 | $4.30 mm |
| Efficient Wealth Management | 250.00 | $2.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Dec 24 | Carin Canale-Theakston | Stock Option Common Stock | Grant | Acquire A | No | No | 22.81 | 16,000 | 364.96 k | 16,000 |
| 17 Dec 24 | Bassler Bonnie L | Stock Option Common Stock | Grant | Acquire A | No | No | 22.81 | 16,000 | 364.96 k | 16,000 |
| 17 Dec 24 | Mineo Chrysa | Stock Option Common Stock | Grant | Acquire A | No | No | 22.81 | 19,000 | 433.39 k | 19,000 |
| 17 Dec 24 | Theodore R Schroeder | Stock Option Common Stock | Grant | Acquire A | No | No | 22.81 | 20,500 | 467.61 k | 20,500 |
| 17 Dec 24 | Burgess Daniel D | Stock Option Common Stock | Grant | Acquire A | No | No | 22.81 | 20,500 | 467.61 k | 20,500 |
